UCB (EBR:UCB) | WebDisclosure

Basculer en Français

10371	Companies
216166	Keywords
145880	Articles
114460	Press releases

BRIEF

published on 12/08/2025 at 07:45, 5 months 1 day ago

UCB Reports Positive Phase 3 Trial Results for Fenfluramine in CDKL5 Disorder

UCB Phase 3 Study Fenfluramine CDKL5 Deficiency Seizure Reduction
BRIEF

published on 12/08/2025 at 07:45, 5 months 1 day ago

UCB annonce des résultats positifs pour son essai de phase 3 sur la fenfluramine dans le traitement du syndrome CDKL5

UCB Étude De Phase 3 Fenfluramine Déficit En CDKL5 Réduction Des Crises
PRESS RELEASE

published on 12/08/2025 at 07:40, 5 months 1 day ago

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
UCB presents positive results from GEMZ phase 3 study at AES showing significant reduction in countable motor seizure frequency in CDKL5 Deficiency Disorder. Study demonstrates efficacy and safety of fenfluramine as adjunctive treatment

AES UCB Fenfluramine Seizure Reduction GEMZ Phase 3 Study

Accesswire

Published on 05/09/2026 at 01:55, 9 hours 33 minutes ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 9 hours 48 minutes ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 9 hours 58 minutes ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 11 hours 28 minutes ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 12 hours 27 minutes ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 05/08/2026 at 20:38, 14 hours 50 minutes ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 16 hours 15 minutes ago

EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 16 hours 25 minutes ago

Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/08/2026 at 18:29, 16 hours 59 minutes ago

Designated Person Notification
Published on 05/08/2026 at 18:29, 16 hours 59 minutes ago

Designated Person Notification

Les Echos

Published on 05/07/2026 at 19:15, 1 day 16 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 16 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 day 16 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 day 16 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 day 16 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE